Invitrogen Launches Biomarker Tool for Pre-Clinical Research into Kidney Function
Product News Aug 03, 2009
Invitrogen has announced the global availability of a new biomarker tool for use in pre-clinical research into kidney function. The PlexMark™ 3 Renal Biomarker Panel Assay is a non-invasive and cost-effective research tool for performing post-transplantation kidney function studies.
The introduction of this research tool will help in the development of studies which may lead to more effective methods for monitoring kidney health in transplant research, the company expects.
This new assay provides researchers with an alternative to invasive and expensive procedures, such as biopsies, used to obtain kidney tissue samples to allow research into post-transplantation kidney function.
The PlexMark 3 Renal Biomarker Panel Assay measures levels of cytokines, chemokines and receptor levels in urine, which can give researchers a better understanding of immune function and response. This may lead to the development of new, non-invasive tests to monitor kidney function and health following transplant procedures.
The PlexMark assay uses Luminex® xMAP® multiplexing technology for bioassay analysis, in a standard immunoassay format to offer sensitivity and reproducible results. The biomarkers in the PlexMark panel are licensed from Renovar Inc, a developer of new tools for assessing kidney inflammation for numerous clinical indications.